Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial
2009 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial
Schoof, N.; von Bonin, F.; Zeynalova, S.; Ziepert, M.; Jung, W.; Loeffler, M. & Pfreundschuh, M. et al. (2009)
Annals of Oncology, 20(9) pp. 1548-1554. DOI: https://doi.org/10.1093/annonc/mdp110
Documents & Media
closedAccess2.25 MBAdobe PDF
Details
- Authors
- Schoof, Nils; von Bonin, Frederike; Zeynalova, Samira; Ziepert, Marita; Jung, Werner; Loeffler, Markus; Pfreundschuh, Michael; Truemper, Lorenz H.; Kube, Dieter
- Abstract
- Methods: In 228 DLBCL samples of the German High-Grade Non-Hodgkin's Lymphoma Study Group, the polymorphisms of IL4 (-524CT, rs2243250), IL13 (-1069CT, rs1800925) and IL4R (I75V, rs1805010; S503P, rs1805015; Q576R, rs1801275) were analyzed and the soluble interleukin-4 receptor (sIL4R) serum level was measured before the start of chemotherapy. Results: Patients harboring IL4R V75 (IL4R(I75V-AG) and IL4R(I75V-GG)) had shorter overall survival (OS) (P = 0.044) and event-free survival (EFS) (P = 0.056) periods compared with I75 carriers (IL4R(I75V-AA)). Multivariate analysis adjusted to the International Prognostic Index revealed a relative risk of 1.9 for carriers of the IL4R V75 (P = 0.011) in relation to OS. DLBCL patients homozygous for the IL4R I75 and low sIL4R serum levels have the most favorable OS and EFS. Conclusions: These data support the role for host germline gene variations of immunologically important factors like the IL4R I75V gene variation to predict the survival in DLBCL patients.
- Issue Date
- 2009
- Status
- published
- Publisher
- Oxford Univ Press
- Journal
- Annals of Oncology
- ISSN
- 0923-7534